published meta-analysis   sensitivity analysis   studies

losartan in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsUniversity of Minnesota, 2020 1.29 [0.51; 3.26] 1.29[0.51; 3.26]University of Minnesota, 202010%205NAnot evaluable deathsdetailed resultsUniversity of Minnesota, 2020 0.68 [0.11; 4.16] 0.68[0.11; 4.16]University of Minnesota, 202010%205NAnot evaluable hospital dischargedetailed resultsUniversity of Minnesota, 2020 0.64 [0.37; 1.11] 0.64[0.37; 1.11]University of Minnesota, 202010%205NAnot evaluable hospitalizationdetailed resultsUniversity of Minnesota, 2020 1.63 [0.94; 2.85] 1.63[0.94; 2.85]University of Minnesota, 202010%205NAnot evaluable mechanical ventilationdetailed resultsUniversity of Minnesota, 2020 1.34 [0.66; 2.73] 1.34[0.66; 2.73]University of Minnesota, 202010%203NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-28 19:19 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 891 - roots T: 290